Compare TDS & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDS | IRTC |
|---|---|---|
| Founded | 1968 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 1997 | 2016 |
| Metric | TDS | IRTC |
|---|---|---|
| Price | $33.82 | $123.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $53.33 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 1.0M | 688.6K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | 23.53 | ★ 61.71 |
| EPS | ★ 3.50 | N/A |
| Revenue | ★ $1,228,207,000.00 | $747,138,000.00 |
| Revenue This Year | $4.05 | $19.60 |
| Revenue Next Year | $1.72 | $15.94 |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $31.51 | $100.85 |
| 52 Week High | $49.12 | $210.01 |
| Indicator | TDS | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 52.76 |
| Support Level | $31.51 | $114.93 |
| Resistance Level | $35.13 | $125.60 |
| Average True Range (ATR) | 1.24 | 6.38 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 37.06 | 41.98 |
Telephone and Data Systems Inc is a diversified telecommunications operator that provides communications services to customers through broadband, video, voice, and wireless connections. The company has two reportable segments: TDS Telecom and Array. The majority of its revenue is generated from the TDS Telecom segment, which generates revenue by providing broadband, video, voice, and wireless services. The Array segment generates its revenue mainly by leasing tower space on Array-owned towers to customers.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.